Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.808 ^USD	-1.46%		-2.65%	+44.29%

Jun. 28	Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies	MT
Jun. 28	Transcript : Tiziana Life Sciences Ltd - Special Call

Tiziana Life Sciences PLC announces an Equity Buyback for $5 million worth of its shares.

January 24, 2022 at 11:53 am EST

Tiziana Life Sciences PLC (NasdaqGM:TLSA) announces a share repurchase program. Under the program, the company will repurchase up to $5 million worth of its shares. The program will be funded using the company's working capital.

The program will run until December 31, 2022.

Latest news about Tiziana Life Sciences Ltd

Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies	Jun. 28	MT
Transcript : Tiziana Life Sciences Ltd - Special Call	Jun. 27
Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; Nvidia to Decline, Micron Technology to Open Higher	Jun. 24	MT
Tiziana Says FDA Accepts Fast Track Label Submission For Multiple Sclerosis Treatment	Jun. 11	MT
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis	Jun. 11	CI
Tiziana Life Sciences' Foralumab Demonstrates Qualitative Improvement in Multiple Sclerosis Patients After 6 Months Use	Jun. 06	MT
Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program	Jun. 06	CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	May. 10	CI
Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	Apr. 25	CI
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23	MT
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	Apr. 23	MT
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	Apr. 23	CI
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	Apr. 22	CI
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	Apr. 19	CI
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 18	CI
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	CI
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	Jan. 05	MT
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05	CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 30	CI
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis	Dec. 19	CI
Transcript : Tiziana Life Sciences Ltd - Shareholder/Analyst Call	Dec. 14
Tiziana Life Sciences Doses Four New Patients in Multiple-Sclerosis Program	Nov. 30	MT
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis	Nov. 30	CI
Tiziana Life Sciences Says FDA Allows At-Home Use of Multiple Sclerosis Treatment; Shares Rise	23-10-18	MT
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment	23-10-18	CI

Chart Tiziana Life Sciences Ltd

Duration

Period

More charts

Company Profile

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TIZIANA LIFE SCIENCES LTD	+44.29%	82.02M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research